Press Release
Change in the Biohit Oyj’s Management Team
Publishing on January 14, 2026 at 10:30 am local time (EET)
Panu Hendolin, Chief Technology Officer (CTO) and a member of the management team of Biohit Oyj, has resigned.
The company thanks Mr. Hendolin for his contribution. During his long career at Biohit, he has supported the company’s development and the strengthening of its technological expertise.
Kati Piironen has been appointed to the management team to succeed Mr. Hendolin. She serves as the company’s R&D Director. Ms. Piironen has been employed by Biohit since 2024. She holds a PhD in pharmaceutical chemistry, and has broad experience in product development, particularly in diagnostic technologies. Her expertise supports the further development of the company’s research and development activities to meet future needs.
The change takes effect immediately.
Additional information:
Jussi Hahtela, CEO, Biohit Oyj, tel. +358 50 383 5948
investor.relations@biohit.fi
www.biohithealthcare.com
Biohit in brief
Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com